Literature DB >> 16814753

Transient ischemia-induced changes of interleukin-2 and its receptor beta immunoreactivity and levels in the gerbil hippocampal CA1 region.

In Koo Hwang1, Ki-Yeon Yoo1, Dae Won Kim2, Hak-Ju Lee3, Ha-Young Kang3, Hyeon-Yong Lee4, Tae-Cheon Kang1, Soo Young Choi2, Yong-Sun Kim5, Moo Ho Won6.   

Abstract

Interlukin-2 (IL-2) is an important cytokine in the brain: IL-2 and its receptors are involved with inflammatory processes. Chronological changes in IL-2 level in serum, and IL-2 and its receptor (IL-2 receptor beta, IL-2Rbeta) immunoreactivities and levels were examined in the hippocampal CA1 region after transient forebrain ischemia in gerbils. IL-2 level in serum significantly decreased 12 h after ischemia/reperfusion. IL-2 immunoreactivity was detected in the somata of pyramidal cells in sham-operated group. At 15 min after ischemia, IL-2 immunoreactivity was shown in non-pyramidal cells as well as pyramidal cells. One day after ischemia, IL-2 immunoreactivity was lowest, and IL-2 immunoreactivity is shown in non-pyramidal cells from 2 days after ischemia. Four days after ischemia, IL-2 immunoreactivity was shown in dying pyramidal cells. IL-2Rbeta immunoreactivity in the sham-operated and 15 min-3 min post-ischemic groups is detected in the cell membrane of pyramidal cells. From 3 h after ischemia, IL-2Rbeta immunoreactivity is found in cytoplasm and nuclei, but not in cell membrane. IL-2Rbeta immunoreactivity decreases from 6 h after ischemia and is shown mainly in non-pyramidal cells from 3 days after ischemia. The data of Western blot analyses for IL-2 and IL-2Rbeta was similar to the immunohistochemical data. IL-2 infusion into cerebrospinal fluid did not protect hippocampal neurons from ischemic damage. These results suggest that IL-2 and IL-2Rbeta show malfunction from 3 h after ischemia, and exogenous IL-2 does not protect ischemic neuronal damage.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16814753     DOI: 10.1016/j.brainres.2006.05.098

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  5 in total

1.  Neuroprotection of Ischemic Preconditioning is Mediated by Anti-inflammatory, Not Pro-inflammatory, Cytokines in the Gerbil Hippocampus Induced by a Subsequent Lethal Transient Cerebral Ischemia.

Authors:  Dong Won Kim; Jae-Chul Lee; Jeong-Hwi Cho; Joon Ha Park; Ji Hyeon Ahn; Bai Hui Chen; Bich-Na Shin; Hyun-Jin Tae; Jeong Yeol Seo; Jun Hwi Cho; Il Jun Kang; Seongkweon Hong; Young-Myeong Kim; Moo-Ho Won; In Hye Kim
Journal:  Neurochem Res       Date:  2015-08-20       Impact factor: 3.996

2.  Chronological changes in inflammatory cytokines immunoreactivities in the mouse hippocampus after systemic administration of high dosage of tetanus toxin.

Authors:  Bing Chun Yan; Joon Ha Park; In Hye Kim; Bich Na Shin; Ji Hyeon Ahn; Ki-Yeon Yoo; Deuk-Sik Lee; Myong Jo Kim; Il-Jun Kang; Moo-Ho Won
Journal:  Exp Brain Res       Date:  2012-09-19       Impact factor: 1.972

3.  Comparison of expression of inflammatory cytokines in the spinal cord between young adult and aged beagle dogs.

Authors:  Dae Hwan Lee; Ji Hyeon Ahn; Joon Ha Park; Bing Chun Yan; Jeong-Hwi Cho; In Hye Kim; Jae-Chul Lee; Sang-Hun Jang; Myoung Hyo Lee; In Koo Hwang; Seung Myung Moon; Bonghee Lee; Jun Hwi Cho; Hyung-Cheul Shin; Jin Sang Kim; Moo-Ho Won
Journal:  Cell Mol Neurobiol       Date:  2013-04-20       Impact factor: 5.046

4.  Pretreatment with apoaequorin protects hippocampal CA1 neurons from oxygen-glucose deprivation.

Authors:  Julia A Detert; Erin L Adams; Jacob D Lescher; Jeri-Anne Lyons; James R Moyer
Journal:  PLoS One       Date:  2013-11-11       Impact factor: 3.240

5.  Neuroprotection of Chrysanthemum indicum Linne against cerebral ischemia/reperfusion injury by anti-inflammatory effect in gerbils.

Authors:  Ki-Yeon Yoo; In Hye Kim; Jeong-Hwi Cho; Ji Hyeon Ahn; Joon Ha Park; Jae-Chul Lee; Hyun-Jin Tae; Dae Won Kim; Jong-Dai Kim; Seongkweon Hong; Moo-Ho Won; Il Jun Kang
Journal:  Neural Regen Res       Date:  2016-02       Impact factor: 5.135

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.